Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,900 signal articles · 164 in last 24h · 135,512 total before filter · latest 2h ago
164last 24h
1098last 7d
178● bullish (7d)
143● bearish (7d)
209publishers
AllMacro304Earnings354M&A78Regulatory24Product11Analyst16
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
HIVE Digital Technologies Q1 Earnings Call Highlights
MarketBeat18d agoneutral
HIVE Digital Technologies Q1 Earnings Call Highlights

HIVE Digital Technologies (NASDAQ:HIVE) reported fiscal first-quarter 2027 revenue of $79.1 million, up 73% from $45.6 million a year earlier and 10% sequentially, as the company expanded its Bitcoin mining operations and continued building its high-performance computing, or HPC, and artificial inte

ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?
StockStory18d agoneutral
ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?

ICU Medical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 9.3%. The stock now trades at $182.79, marking a 23.3% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Syntec Optics Q2 Earnings Call Highlights
MarketBeat18d agoneutral
Syntec Optics Q2 Earnings Call Highlights

Syntec Optics (NASDAQ:OPTX) reported record second-quarter revenue for 2026, returning to operating and net profitability as sales increased across its medical, defense, consumer and communications markets. Revenue for the quarter totaled approximately $8.3 million, up 26% from approximately $6.6 m

DeFi Development Q2 Earnings Call Highlights
MarketBeat18d agoneutral
DeFi Development Q2 Earnings Call Highlights

DeFi Development (NASDAQ:DFDV) used its second-quarter 2026 earnings update call to emphasize its strategy of building long-term Solana per-share exposure through validator operations, on-chain deployment and leverage, while simplifying its capital structure and reducing noncore complexity. Chief E

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?
StockStory19d agoneutral
Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Zoom (ZM): Buy, Sell, or Hold Post Q1 Earnings?
StockStory19d agoneutral
Zoom (ZM): Buy, Sell, or Hold Post Q1 Earnings?

Over the past six months, Zoom has been a great trade, beating the S&P 500 by 10.4%. Its stock price has climbed to $109.49, representing a healthy 23.5% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.